372 related articles for article (PubMed ID: 24456319)
41. Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy.
Mellado M; Pijoan JI; Jiménez D; Muriel A; Aujesky D; Bertoletti L; Decousus H; Barrios D; Clará A; Yusen RD; Monreal M;
JACC Cardiovasc Interv; 2016 Dec; 9(23):2440-2448. PubMed ID: 27838262
[TBL] [Abstract][Full Text] [Related]
42. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.
Carroll B; Irwin DE
J Manag Care Spec Pharm; 2019 Jul; 25(7):810-816. PubMed ID: 31232207
[TBL] [Abstract][Full Text] [Related]
43. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
[TBL] [Abstract][Full Text] [Related]
44. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
[TBL] [Abstract][Full Text] [Related]
45. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
46. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States.
Secemsky EA; Rosenfield K; Kennedy KF; Jaff M; Yeh RW
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29945913
[TBL] [Abstract][Full Text] [Related]
47. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.
MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J
Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S5-15. PubMed ID: 17032933
[TBL] [Abstract][Full Text] [Related]
48. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
49. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
50. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
51. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
[TBL] [Abstract][Full Text] [Related]
52. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
53. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
54. Duration of anticoagulant therapy and VTE recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J
Support Care Cancer; 2019 Oct; 27(10):3833-3840. PubMed ID: 30734088
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
[TBL] [Abstract][Full Text] [Related]
56. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
57. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
58. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Patel AA; Ogden K; Mody SH; Bookhart B
J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
[TBL] [Abstract][Full Text] [Related]
59. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
[TBL] [Abstract][Full Text] [Related]
60. Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism.
Monahan M; Ensor J; Moore D; Fitzmaurice D; Jowett S
J Thromb Haemost; 2017 Aug; 15(8):1591-1600. PubMed ID: 28520199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]